Organization: Department of Epidemiology & Biostatistics, School of Medicine, University of California, San Francisco
Country: United States
Susan Buchbinder is the Director of Bridge HIV, a grant-funded HIV prevention research unit housed in the San Francisco Department of Public Health, and a Clinical Professor of Medicine, Epidemiology and Biostatistics at the University of California, San Francisco (UCSF). She received her undergraduate degree from Brown University and her MD from UCSF, where she completed a residency in primary care internal medicine. She has been providing care as an attending physician at the Richard Fine People’s Clinic at San Francisco General Hospital since completing her training. She teaches in the Advanced Traineeship in Clinical Research Program at UCSF and mentors students, residents, fellows and faculty.
She began her research career studying long-term HIV non-progressors and risk factors for disease progression in the San Francisco City Clinic Cohort, at the time, the longest-standing natural history study of sexually acquired HIV. Since then, her research has focused on risk factors for HIV acquisition and evaluating different strategies for reducing HIV incidence, including HIV vaccines and monoclonal antibodies, pre-exposure prophylaxis, topical vaginal and rectal agents, home HIV testing, combination strategies and technology to support these interventions. Addressing racial/ethnic and gender disparities has been a central focus of her work.
Susan has contributed to various CDC- and NIH-sponsored clinical trials networks, currently serving on the Executive Management Team of the HIV Vaccine Trials Network, where she chairs the Efficacy Trials Working Group. She is Chair of the Mosaico Phase 3 vaccine trial being conducted in the Americas and Europe, and Co-Chair of the Imbokodo Phase 3 vaccine trial in five sub-Saharan African countries. She co-leads the San Francisco Bay Clinical Trials Unit. She has chaired and served on the Scientific Program Committee of the Conference on Retroviruses and Opportunistic Infections (CROI) and the HIV Research for Prevention (HIVR4P) meetings. She currently serves as Chair of the Enterprise Advisory Group of the Global HIV Vaccine Enterprise.
With Diane Havlir, she co-founded San Francisco Getting to Zero, a multi-sector consortium of more than 300 members built on a collective impact framework, to achieve zero HIV acquisitions, zero HIV-associated deaths and zero HIV stigma and discrimination in San Francisco.